Peer-Review Record
Correction: Wind et al. Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial. Cancers 2022, 14, 1510
Cancers 2023, 15(5), 1485; https://doi.org/10.3390/cancers15051485
by
Selinde S. Wind 1,2
, Manon A. A. Jansen 1, Melanie Rijsbergen 1, Michiel J. van Esdonk 1, Dimitrios Ziagkos 1, Wing C. Cheng 1, Tessa Niemeyer-van der Kolk 1, John Korsten 3, Agnieszka Gruszka 3, Debora Schmitz-Rohmer 4, David Bonnel 5, Raphael Legouffe 5, Florian Barré 5, Marcel W. Bekkenk 6, Ellen R. M. de Haas 7, Koen D. Quint 2, Harald Schnidar 8, Melanie Rolli 4, Henk Johan Streefkerk 4, Jacobus Burggraaf 1,2,9, Maarten H. Vermeer 2 and add
Show full author list
, Manon A. A. Jansen 1, Melanie Rijsbergen 1, Michiel J. van Esdonk 1, Dimitrios Ziagkos 1, Wing C. Cheng 1, Tessa Niemeyer-van der Kolk 1, John Korsten 3, Agnieszka Gruszka 3, Debora Schmitz-Rohmer 4, David Bonnel 5, Raphael Legouffe 5, Florian Barré 5, Marcel W. Bekkenk 6, Ellen R. M. de Haas 7, Koen D. Quint 2, Harald Schnidar 8, Melanie Rolli 4, Henk Johan Streefkerk 4, Jacobus Burggraaf 1,2,9, Maarten H. Vermeer 2 and add
Show full author list
Cancers 2023, 15(5), 1485; https://doi.org/10.3390/cancers15051485
Submission received: 24 October 2022
/
Accepted: 7 November 2022
/
Published: 27 February 2023
(This article belongs to the Special Issue Therapeutic Monitoring of Anti-cancer Agents)
